AIM ImmunoTech(AIM)
搜索文档
AIM ImmunoTech(AIM) - 2019 Q4 - Annual Report
2020-03-31 05:22
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 000-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | --- | |----------------- ...
AIM ImmunoTech(AIM) - 2019 Q3 - Quarterly Report
2019-11-15 05:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share AIM NYSE American FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2019 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdictio ...
AIM ImmunoTech(AIM) - 2019 Q2 - Quarterly Report
2019-08-15 04:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2019 Commission File Number: 1-13441 HEMISPHERX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) | --- | --- | |---------------------------------------------------------------------------------------------------------|------------------------------------------| | (State or other ...
AIM ImmunoTech(AIM) - 2019 Q1 - Quarterly Report
2019-05-16 04:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share HEB NYSE American FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2019 Commission File Number: 1-13441 HEMISPHERX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdicti ...
AIM ImmunoTech(AIM) - 2018 Q4 - Annual Report
2019-04-02 05:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 000-27072 HEMISPHERX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other j ...